Patients that as part of their routine clinical care and according to the locally approved label, are either;

Starting fingolimod at time of study entry.

Starting another approved DMT or started within maximum 6 months prior to study entry.

Patients, or a able legal representative of the patient, who are willing to provide written informed consent.

Fingolimod patients will constitute the fingolimod cohort while patients with the other DMT will constitute the parallel cohort

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies